11/20
10:12 am
gmab
BioNJ Unveils "Time Off for Clinical Trials" Initiative [Yahoo! Finance]
Low
Report
BioNJ Unveils "Time Off for Clinical Trials" Initiative [Yahoo! Finance]
11/8
10:34 am
gmab
Genmab A/S (NASDAQ: GMAB) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $48.00 price target on the stock, up previously from $46.00.
Low
Report
Genmab A/S (NASDAQ: GMAB) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $48.00 price target on the stock, up previously from $46.00.
11/8
02:21 am
gmab
High Growth Tech Stocks To Watch In November 2024 [Yahoo! Finance]
Low
Report
High Growth Tech Stocks To Watch In November 2024 [Yahoo! Finance]
11/6
11:10 am
gmab
Genmab Announces Financial Results for the First Nine Months of 2024 [Yahoo! Finance]
Low
Report
Genmab Announces Financial Results for the First Nine Months of 2024 [Yahoo! Finance]
11/6
11:01 am
gmab
Genmab Announces Financial Results for the First Nine Months of 2024
Low
Report
Genmab Announces Financial Results for the First Nine Months of 2024
11/5
12:13 pm
gmab
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting [Yahoo! Finance]
Low
Report
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting [Yahoo! Finance]
11/5
12:00 pm
gmab
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
Low
Report
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
10/16
11:52 am
gmab
Is the Options Market Predicting a Spike in Genmab (GMAB) Stock? [Yahoo! Finance]
Low
Report
Is the Options Market Predicting a Spike in Genmab (GMAB) Stock? [Yahoo! Finance]
10/16
08:31 am
gmab
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Low
Report
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
10/15
11:54 am
gmab
Is Genmab (GMAB) Stock Undervalued Right Now? [Yahoo! Finance]
Low
Report
Is Genmab (GMAB) Stock Undervalued Right Now? [Yahoo! Finance]
10/15
07:53 am
gmab
Johnson & Johnson posts Q3 beat; lowers earnings guidance amid M&A impact [Seeking Alpha]
Low
Report
Johnson & Johnson posts Q3 beat; lowers earnings guidance amid M&A impact [Seeking Alpha]
10/15
06:25 am
gmab
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024
Low
Report
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024
10/11
09:30 am
gmab
Life Science Washington Institute Recognizes ProfoundBio Co-Founders with 2024 Entrepreneurial Achievement Award
Low
Report
Life Science Washington Institute Recognizes ProfoundBio Co-Founders with 2024 Entrepreneurial Achievement Award
10/8
07:32 am
gmab
Genmab A/S (NASDAQ: GMAB) is now covered by analysts at Redburn Atlantic. They set a "buy" rating on the stock.
Low
Report
Genmab A/S (NASDAQ: GMAB) is now covered by analysts at Redburn Atlantic. They set a "buy" rating on the stock.
10/4
02:00 pm
gmab
Major Shareholder Announcement [Yahoo! Finance]
Low
Report
Major Shareholder Announcement [Yahoo! Finance]
10/4
01:55 pm
gmab
Major Shareholder Announcement
Low
Report
Major Shareholder Announcement
10/1
04:27 pm
gmab
Should You Buy AbbVie Stock After Recent Parkinson's Study Success? [Yahoo! Finance]
Low
Report
Should You Buy AbbVie Stock After Recent Parkinson's Study Success? [Yahoo! Finance]
9/20
08:12 am
gmab
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Low
Report
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
9/17
06:48 am
gmab
BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024 [Yahoo! Finance]
Low
Report
BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024 [Yahoo! Finance]
9/15
08:45 am
gmab
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
Low
Report
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
9/13
08:02 am
gmab
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Low
Report
Genmab A/S (NASDAQ: GMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
9/11
12:19 pm
gmab
Genmab A/S (NASDAQ: GMAB) had its "equal weight" rating re-affirmed by analysts at Morgan Stanley. They now have a $31.00 price target on the stock.
Low
Report
Genmab A/S (NASDAQ: GMAB) had its "equal weight" rating re-affirmed by analysts at Morgan Stanley. They now have a $31.00 price target on the stock.
9/9
10:04 am
gmab
Genmab A/S (NASDAQ: GMAB) had its price target lowered by analysts at Truist Financial Co. from $53.00 to $50.00. They now have a "buy" rating on the stock.
Low
Report
Genmab A/S (NASDAQ: GMAB) had its price target lowered by analysts at Truist Financial Co. from $53.00 to $50.00. They now have a "buy" rating on the stock.
9/4
08:06 am
gmab
Genmab A/S (NASDAQ: GMAB) had its "equal weight" rating re-affirmed by analysts at Morgan Stanley. They now have a $31.00 price target on the stock.
Low
Report
Genmab A/S (NASDAQ: GMAB) had its "equal weight" rating re-affirmed by analysts at Morgan Stanley. They now have a $31.00 price target on the stock.
8/30
06:04 pm
gmab
Genmab A/S (GMAB): One of the Best Affordable Stocks Under $40 According to Short Sellers [Yahoo! Finance]
Low
Report
Genmab A/S (GMAB): One of the Best Affordable Stocks Under $40 According to Short Sellers [Yahoo! Finance]